These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37036164)

  • 1. Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-NTRK3 fusion.
    Zhou K; Gong D; He C; Xiao M; Zhang M; Huang W
    Mol Carcinog; 2023 Jul; 62(7):899-906. PubMed ID: 37036164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement.
    Nardi V; Ku N; Frigault MJ; Dubuc AM; Tsai HK; Amrein PC; Hobbs GS; Brunner AM; Narayan R; Burke ME; Foster J; Dal Cin P; Maus MV; Fathi AT; Hock H
    Blood Adv; 2020 Jan; 4(1):106-111. PubMed ID: 31905241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of monitoring ETV6-RUNX1 fusion gene expression in children with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Hong Y; Qin YZ; Xu YY; Zhou SH; Wang Y; Xu LP; Zhang XH; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2017 Aug; 38(8):680-684. PubMed ID: 28954346
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.
    Xiao H; Wang LM; Luo Y; Lai X; Li C; Shi J; Tan Y; Fu S; Wang Y; Zhu N; He J; Zheng W; Yu X; Cai Z; Huang H
    Oncotarget; 2016 Jan; 7(3):2696-708. PubMed ID: 26527318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
    Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
    Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.
    Hoffmann J; Krumbholz M; Gutiérrez HP; Fillies M; Szymansky A; Bleckmann K; Zur Stadt U; Köhler R; Kuiper RP; Horstmann M; von Stackelberg A; Eckert C; Metzler M
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27780. PubMed ID: 31034759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review].
    Zuo Y; Wang J; Lu A; Jia Y; Wu J; Dong L; Chang L; Zhang L
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):115-8. PubMed ID: 27014980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-HSCT Maintenance Treatment Using Entrectinib for an AML Patient Accompanied with ETV6::NTRK3: A Case Report.
    Zhao X; Hao M; Zhang X; Wei J; Feng S; He Y; Jiang E; Han M
    Onco Targets Ther; 2023; 16():1055-1059. PubMed ID: 38144903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol.
    Gandemer V; Chevret S; Petit A; Vermylen C; Leblanc T; Michel G; Schmitt C; Lejars O; Schneider P; Demeocq F; Bader-Meunier B; Bernaudin F; Perel Y; Auclerc MF; Cayuela JM; Leverger G; Baruchel A;
    Haematologica; 2012 Nov; 97(11):1743-50. PubMed ID: 22580999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
    Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
    Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Hong Y; Zhao X; Qin Y; Zhou S; Chang Y; Wang Y; Zhang X; Xu L; Huang X
    Ann Hematol; 2018 Sep; 97(9):1547-1554. PubMed ID: 29705861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 priming chemotherapy: a strategy to improve the remission of refractory/relapsed T cell acute lymphoblastic leukemia.
    Zhang C; Zhang X; Chen XH
    Med Hypotheses; 2013 Nov; 81(5):878-80. PubMed ID: 24074835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Identification of a novel
    Yu QX; Zhao WJ; Wang HY; Zhang L; Qin L; Zhang L; Han JL
    Front Oncol; 2023; 13():1123812. PubMed ID: 37188179
    [No Abstract]   [Full Text] [Related]  

  • 17. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
    Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
    Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and Prognostic Factors for
    Lee JW; Kim SK; Jang PS; Chung NG; Jeong DC; Kim M; Cho B; Kim HK
    Cancer Res Treat; 2017 Apr; 49(2):446-453. PubMed ID: 27506214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
    Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.